Geoffrey M. Parker - 25 Jan 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
25 Jan 2024
Net transactions value
$0
Form type
4
Filing time
31 Jan 2024, 17:47:41 UTC
Previous filing
20 Dec 2023
Next filing
06 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +29,400 +3.7% $0.000000 819,400 25 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +103,939 $0.000000 103,939 25 Jan 2024 Common Stock 103,939 $3.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter.